Treace Medical Concepts (TMCI)
Builds surgical systems for bunion and related midfoot deformity procedures.
$4.51
vs last close−0.08 (−1.70%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 41 | 62 | 51 | 44 | 45 | 69 | 53 | 47 | 50 | 63 | 47 | 45 |
| Cost of revenue | 8 | 11 | 10 | 9 | 9 | 13 | 11 | 10 | 11 | 12 | 10 | 10 |
| Gross profit | 33 | 51 | 41 | 36 | 36 | 55 | 42 | 38 | 40 | 50 | 37 | 36 |
| 51 | 58 | 60 | 57 | 51 | 56 | 57 | 55 | 55 | 56 | 55 | 51 | |
| Research & development | 4 | 4 | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 5 | 5 | 4 |
| 46 | 53 | 55 | 52 | 46 | 50 | 52 | 49 | 50 | 52 | 50 | 46 | |
| Selling & marketing | 34 | 40 | 40 | 38 | 33 | 37 | 36 | 33 | 33 | 37 | 34 | 31 |
| General & administrative | 13 | 13 | 14 | 14 | 14 | 14 | 16 | 16 | 16 | 15 | 16 | 15 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Operating income | −18 | −7 | −19 | −21 | −15 | 0 | −16 | −17 | −16 | −6 | −17 | −15 |
| 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | −1 | −3 | −1 | −1 | |
| Interest income | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 |
| Interest expense | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Other non-operating income | −2 | −2 | −2 | −1 | −1 | −1 | −1 | −1 | −1 | 2 | −1 | −1 |
| Income before tax | −18 | −6 | −19 | −21 | −15 | −1 | −16 | −17 | −16 | −9 | −18 | −16 |
| Net income from continuing operations | −18 | −6 | −19 | −21 | −15 | −1 | −16 | −17 | −16 | −9 | −18 | −16 |
| Net income | −18 | −6 | −19 | −21 | −15 | −1 | −16 | −17 | −16 | −9 | −18 | −16 |
| EPS, basic | −$0.28 | −$0.10 | −$0.30 | −$0.34 | −$0.25 | −$0.01 | −$0.25 | −$0.28 | −$0.26 | −$0.15 | −$0.28 | −$0.24 |
| EPS, diluted | −$0.28 | −$0.10 | −$0.30 | −$0.34 | −$0.25 | −$0.01 | −$0.25 | −$0.28 | −$0.26 | −$0.15 | −$0.28 | −$0.24 |
| Weighted average shares, basic | 62 | 62 | 62 | 62 | 62 | 62 | 63 | 63 | 64 | 64 | 65 | 65 |
| Weighted average shares, diluted | 62 | 62 | 62 | 62 | 62 | 62 | 63 | 63 | 64 | 64 | 65 | 65 |
| EBITDA | −15 | −3 | −15 | −18 | −12 | 3 | −12 | −14 | −12 | −5 | −15 | −12 |
| Depreciation & amortization | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 1 | 2 |
| EBIT | −16 | −5 | −17 | −20 | −14 | 1 | −15 | −16 | −15 | −8 | −16 | −14 |
